The multiple kinase inhibitor Sunitinib is an inhibitor of VEGF, PDGFR, FLT1, FLT1/KDR, FLT3 and the RET kinases.59 In a phase II study for recurrent glioblastoma multiforme, Sunitinib was found to be unsuitable as a monotherapy with all patients’ disease progressing despite treatment.60 Here, VEGFA is linked to glioblastoma.